Greenstone Heather, Spinelli Beth, Tseng Christopher, Peacock Susan, Taylor Katherine, Laughlin Catherine
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
Antiviral Res. 2008 Apr;78(1):51-9. doi: 10.1016/j.antiviral.2007.10.006. Epub 2007 Nov 9.
Severe viral infections, including hemorrhagic fever and encephalitis, occur throughout the world, but are most prevalent in developing areas that are most vulnerable to infectious diseases. Some of these can also infect related species as illustrated by the threatened extinction of gorillas by Ebola infection in west and central Africa. There are no safe and effective treatments available for these serious infections. In addition to the logistical difficulties inherent in developing a drug for infections that are sporadic and occur mainly in the third world, there is the overwhelming barrier of no hope for return on investment to encourage the pharmaceutical industry to address these unmet medical needs. Therefore, the National Institute of Allergy and infectious Disease (NIAID) has developed and supported a variety of programs and resources to provide assistance and lower the barrier for those who undertake these difficult challenges. The primary programs relevant to the development of therapies for severe viral infections are described and three case studies illustrate how they have been used. In addition, contact information for accessing these resources is supplied.
严重的病毒感染,包括出血热和脑炎,在世界各地都有发生,但在最易受传染病影响的发展中地区最为普遍。其中一些感染还会侵袭相关物种,比如西非和中非的埃博拉感染导致大猩猩濒临灭绝。目前尚无针对这些严重感染的安全有效治疗方法。除了研发针对散发性且主要发生在第三世界国家的感染性疾病药物所固有的后勤困难外,投资回报无望这一巨大障碍也阻碍了制药行业满足这些未被满足的医疗需求。因此,美国国立过敏和传染病研究所(NIAID)制定并支持了各种项目和资源,为应对这些艰巨挑战的人们提供帮助并降低障碍。本文描述了与严重病毒感染治疗方法开发相关的主要项目,并通过三个案例研究说明它们是如何被应用的。此外,还提供了获取这些资源的联系信息。